Clinical Trial Update: Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on re-challenge of anti-EGFR therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Anti-EGFR

Snippet

Sponsor: Yuhong Li | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED